Praxis Precision Medicines, Inc.: insider trades · United States · SEC (Form 4)

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a U.S.-based biopharmaceutical company listed in the United States on NASDAQ, with its headquarters in Boston, Massachusetts, United States. The company was founded around the scientific work of Kiran Reddy, David Goldstein, and Steven Petrou, and its strategy is built on precision medicine for central nervous system disorders. In practice, Praxis focuses on genetically defined or biologically differentiated neurologic diseases, especially severe epilepsies and movement disorders, where targeted oral therapies may offer a meaningful clinical advantage. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1689548/000095012321003591/filename1.htm)) The company’s core engine is its proprietary Cerebrum™ platform, which has produced several clinical-stage candidates. Its lead program is ulixacaltamide, a highly selective T-type calcium channel inhibitor in development for essential tremor. Praxis says it has filed an NDA with the FDA and has already started commercial preparation and pre-launch activities, making this one of the company’s most important near-term value drivers. Relutrigine is being developed for developmental and epileptic encephalopathies (DEEs), including SCN2A-DEE and SCN8A-DEE, and Praxis has submitted an NDA for that program as well. Vormatrigine is advancing in photosensitive epilepsy, with a POWER3 trial expected in the first half of 2026. The company also has PRAX-020, in-licensed from UCB Biopharma SRL, in its portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001689548/000168954826000029/prax-20251231.htm)) From a competitive standpoint, Praxis is differentiated by its precision-CNS approach and by its focus on smaller, high-need patient subsets rather than broad primary-care markets. That can support strong scientific positioning and regulatory optionality, especially given the Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations received by some programs. At the same time, the business remains highly dependent on a limited number of pipeline assets, which is standard for a development-stage biotech but also increases execution risk. The Cerebrum platform is central to the investment case because it is designed to generate multiple first- and best-in-class oral therapies over time. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001689548/000168954826000029/prax-20251231.htm)) Geographically, operations are centered in Boston, and management has stated an intention to reach U.S. prescribers and, where appropriate, expand globally through direct commercialization or partnerships. Recent highlights include positive Phase 3 topline results for ulixacaltamide in the fourth quarter of 2025, the NDA filing for that asset, the NDA filing for relutrigine, and ongoing commercial-readiness work. For investors, PRAX remains a high-beta biotech name with meaningful event-driven upside, but also with the usual clinical, regulatory, financing, and launch-execution risks associated with late-stage CNS drug development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001689548/000168954826000029/prax-20251231.htm))